Article
Generation of SARS-CoV-2 escape mutations by monoclonal antibody therapy.
Nature communications - 7 Jun 2023
Ragonnet-Cronin Manon, Nutalai Rungtiwa, Huo Jiandong, Dijokaite-Guraliuc Aiste, Das Raksha, Tuekprakhon Aekkachai, Supasa Piyada, Liu Chang, Selvaraj Muneeswaran, Groves Natalie, Hartman Hassan, Ellaby Nicholas, Mark Sutton J, Bahar Mohammad W, Zhou Daming, Fry Elizabeth, Ren Jingshan, Brown Colin, Klenerman Paul, Dunachie Susanna J, Mongkolsapaya Juthathip, Hopkins Susan, Chand Meera, Stuart David I, Screaton Gavin R, Rokadiya Sakib
Abstract excerpt
COVID-19 patients at risk of severe disease may be treated with neutralising monoclonal antibodies (mAbs). To minimise virus escape from neutralisation these are administered as combinations e.g. casirivimab+imdevimab or, for antibodies targeting relatively conserved regions, individually e.g. sotrovimab. Unprecedented genomic surveillance of SARS-CoV-2 in the UK has enabled a genome-first approach to detect...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.